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SUMMARY 
The Colonix test is used for the early detection / screening of colorectal cancer and other 
bowel diseases such as inflammatory bowel disease (IBD). An economic model has been 
constructed to estimate the cost-effectiveness of the use of the Colonix device as a pre-
colonoscopy evaluation test in a primary care setting i.e. for patients presenting 
symptomatically to their GP. The aim of using Colonix as a pre-colonoscopy test would be to 
avoid unnecessary colonoscopies as colonoscopy is costly, invasive and comes with a risk of 
perforation. 
A cost effectiveness model was built in Treeage. The population consists of patients who 
have presented to their GP with distal colonic symptoms who were subsequently referred by 
their GP for endoscopic assessment. Essentially the Colonix test will help determine whether 
urgent colonoscopy or an extended observation period is preferable. The model calculates 
costs incurred and QALYs gained over a patient’s life-time.  A life-time horizon was used as it 
is possible that a false negative test result could cause a delay in diagnosis which could 
compromise patient survival thus effecting QALY gains over a patient lifetime. The model 
includes diagnostic test costs and associated costs such as retests and treating bowel 
perforations due to colonoscopy and it includes colorectal cancer treatment costs. The model 
is populated with data relating to diagnostic test characteristics, disease prevalence, 
diagnostic test costs, CRC treatments costs, health state utility values and CRC natural 
history. 
The model output includes the incremental cost effectiveness ratio (ICER), net monetary 
benefit (NMB) and number of colonoscopies avoided. The model structure allows all 
parameters such as Colonix test characteristics, cost of Colonix, etc to be easily updated. 
With the current model assumptions (e.g. patients receiving a true negative Colonix test incur 
no additional diagnosis costs) the use of Colonix is cost-effective at a willingness to pay of 
£20K and has a NMB of just over £200 pounds per person. It will also result in around 60% 
less colonoscopies. 
In constructing the model the importance of correctly representing the treatment pathways 
became evident. Further information relating to the diagnostic pathways for patients receiving 
a negative Colonix result is required to correctly model the economics. Specifically sensitivity 
analyses showed that the model results are highly dependent on the variable ‘cost of 
additional diagnostics following a negative Colonix test’. This cost will be different for patients 
with different underlying conditions and this should be reflected in the modelling. Three 
potential courses of action are suggested: 
1) Collect further subjective clinical judgement relating to diagnostic pathways following 
a negative Colonix result. 
2) Examine what information of patient pathways is obtainable from existing Colonix 
trials – i.e. what subsequent diagnostic tests patients received following a negative 
result. 
3) Undertake a randomized control trial (RCT) to directly compare the two fully defined 
alternative diagnostic pathways (one pathway to represent the existing situation and 
one to include Colonix). 
 
INTRODUCTION 
The Colonix tests are based around the analysis of DNA extracted from exfoliated cells found 
in the rectal mucosa that is found on the surface of the lower inner rectum. The Colonix test is 
used for the early detection / screening of colorectal cancer and other bowel diseases such as 
inflammatory bowel disease (IBD). Here we look at the use of Colonix to evaluate the need for 
colonoscopy in a patient presenting with symptoms associated with colorectal cancer or other 
colorectal diseases in a primary care setting.  
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The largest cost as a proportion of the total cost of illness for bowel cancers is the cost of 
diagnosis which makes up 26% of the overall cost (YHEC report 2007). The diagnosis cost 
includes the cost of referral and diagnosis of all patients who present via a GP, A&E or from 
elsewhere in secondary care.  A large proportion of the diagnosis cost is due to the cost of 
those patients in whom bowel cancer is suspected but who subsequently receive a negative 
diagnosis.  
 
An economic model has been constructed to estimate the cost-effectiveness of the use of the 
Colonix device as a pre-colonoscopy evaluation test in a primary care setting i.e. for patients 
presenting symptomatically to their GP. The aim is to get Colonix approved for use in this 
patient group – and subsequently the aim would be to expand use to other groups. The aim of 
using Colonix as a pre-colonoscopy test would be to avoid unnecessary colonoscopies. 
Colonoscopy is costly, invasive and comes with a risk of perforation. Avoiding unnecessary 
colonoscopies would result in both cost and QALY savings.  
 
Currently no pre-colonoscopy evaluation test is used, (although (Selvachandran 2002) 
describes a questionanaire and scoring system to predict CRC) so the economic evaluation 
will compare Colonix to no pre-colonoscopy test. The model structure is a decision tree which 
compares colonoscopy to Colonix test followed by colonoscopy if the Colonix test result is 
positive. 
 
This document describes the model structure, key assumptions made, data sources and 
results. Areas where further research will be required to complete a NICE submission are 
identified in this report. 
 
 
METHODS 
Model Structure 
The population consists of patients who have presented to their GP with distal colonic 
symptoms who were subsequently referred by their GP for endoscopic assessment. 
Essentially the Colonix test will help determine whether urgent colonoscopy or an extended 
observation period is preferable. 
NHS guidelines describe how symptomatic patients can be classified into low risk or high risk 
when referred by their GP. Patients classified as high risk will be seen within 2 weeks.  
The population considered here consists of patients deemed to be both high and low risk. The 
modelling does not include patients who present to their GP symptomatically but are not 
referred. The use of Colonix in this group of patients may be beneficial but is not currently 
modelled (to do this we would require prevalence information for patients who are not 
referred).  
 
A symptomatic patient may have colorectal cancer or another colorectal condition such as 
inflammatory bowel disease(IBD), polyps, diverticulitis, small benign adenomatous polyps, 
hyperplastic polyps etc. As we are suggesting that Colonix be used in the whole group of 
symptomatic patients these other colorectal conditions must be considered. In the modelling 
we have split the symptomatic population into four groups: cancer, large polyps, IBD 
(including diverticulosis complicated by inflammation) and other. Here other encompasses 
multiple disease states. 
 
IBD encompasses Crohns and ulcerative colitis(UC). UC is a pre-cancerous condition. 
Crohn’s disease and other non-specific inflammations are normally symptomatic and often 
diagnosed by colonoscopy (differential diagnosis with CRC is almost always an issue).  
Colonix may be positive in some patients with diverticulosis aggravated by inflammation 
(diverticulitis) or in patients with growing or multiple polyps. In these cases colonoscopy will 
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be perfectly justified since diverticulitis is often difficult to distinguish from cancer without 
colonoscopy+biopsy, and endoscopic removal of suspicious polyps is a commonly applied 
procedure. 
As the aim of Colonix use is to avoid unnecessary colonoscopies it is important to differentiate 
between conditions which do and don’t require endoscopy. The modelling makes the 
following assumptions:  
 
Conditions requiring colonoscopy: 
•         Cancer 
•         Large polyps  
•         IBD (including diverticulosis complicated by inflammation ie Diverticulitis) 
 
Conditions not requiring colonoscopy: 
•         Small polyps (small benign adenomas, hyperplastic polyps) 
•         Diverticulosis (uncomplicated) 
•         Normal/other -conditions beyond the large bowel or functional disorders (e.g. 
Irritable Bowel Syndrome). 
 
The main purpose of the modelling is to quantify the benefits of avoided colonoscopies. The 
model calculates costs incurred and QALYs gained over a patients life-time.  A life-time 
horizon was used as it is possible that a false negative test result could cause a delay in 
diagnosis which could compromise patient survival thus effecting QALY gains over a patient 
lifetime. The model includes diagnostic test costs and associated costs such as retests and 
treating bowel perforations due to colonoscopy and it includes colorectal cancer treatment 
costs. The model has been built in Treeage, a decision analysis software, which is accepted 
by NICE for submissions. A free trial version of Treeage Pro can be downloaded from 
www.treeage.com/products/download.html and the model can be viewed using this trial 
version. The outline model structure is shown in figure 1. 
 
Where available different diagnostic test characteristic values have been used for sensitivity 
to cancer, polyps and IBD. Test characteristics and prevalence values are used to predict 
numbers of true and false positive and negative diagnoses. The model uses different 
sensitivity values for different groups of colorectal conditions (cancer and large pre-cancerous 
polyps, and IBD). 
 
If a patients Colonix test has heavy contamination it is assumed that a repeat test will be 
given. Colonix have not repeated any contaminated tests in the trials so we have no 
information on whether a repeat test is likely to be contaminated also. The model assumes 
that the repeat test will not be contaminated. It is also assumed that contamination is 
independent to the underlying disease state. 
 
A patient undergoing colonoscopy may experience a complication such as bleeding or a 
bowel perforation which could require treatment or possibly be fatal. Of patients not 
experiencing a fatal bowel perforation there is a possibility that the colonoscopy will be 
incomplete. Currently we assume that of patients who receive an incomplete colonoscopy 
60% have BE and 40% have CT colonography (personal communication – Ian Daniels) and 
that these subsequent tests are always adequate. We assume that patients, who survive 
perforation during colonoscopy have the same characteristics as the non-perforated patients. 
( C Ferret will check the exact percentages for the JRH , Oxford for the last year) 
Patients receiving a false negative test result may experience a delay in diagnosis.  As a 
result a patient may progress to a more advanced cancer stage; this may effect CRC 
treatment costs and patient survival. Hence changes to QOL and cost caused by this delay 
will be modelled. It is assumed that a false negative test result will lead to additional diagnosis 
costs. 
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We will assume that a delayed diagnosis will not effect IBD or diverticulosis treatment costs. It 
is assumed that the utility value for a symptomatic patient with undiagnosed IBD is lower than 
for a patient with a diagnosis. We assume that HRQOL will improve once a diagnosis is 
reached and a patient starts to receive treatment (Allen 2005) 
The economic analysis assumes that future costs and QALYs are discounted at 3.5% per 
annum respectively, in line with current NICE recommendations.   
 
The user defined inputs for the model are: 
Patient age 
Colonix DNA decision threshold 
Willingness to pay threshold 
 
External validation of the model assumptions will be required for a NICE submission. 
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Diagram of model structure 
Figure 1 shows the decision tree structure of the model. The decision tree contains a lot of 
repeated subtrees so for simplicity 10 clones are used to describe the structure and these are 
labelled on the diagram. The structure after the colonoscopy incomplete node is displayed in 
the top (cancer) arm only (again to avoid repetition). For cancer patients (the top arm) the 
proportion of patients diagnosed in each Dukes stage changes if the patient receives a false 
negative and hence a delayed diagnosis. This is achieved using a Boolean variable which is 
set to 1 if the result is a false negative. So for clone 7: CRC diagnosed, the proportion of 
patients diagnosed in each Dukes stage will depend of whether a false negative and a delay 
in diagnosis has been received. 
 
Figure 1: diagram of model structure 
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Table 1 -  Model inputs 
 
Variable Value Source 
Patient age (symptomatic population) 65.00 Colonix London trial data 
Proportion of colonoscopies which are 
complete 0.77 Bowles 2004 
Colonoscopy probability of fatal perforation 0.00 Gatto 2003 
Colonoscopy sensitivity to cancer 0.96 Bressler 2004 
Colonoscopy sensitivity to IBD 0.96 assumed to be same as sensitivity to cancer 
Colonoscopy sensitivity to large polyps 0.96 assumed to be same as sensitivity to cancer 
Colonoscopy test specificity 1.00 assumption due to nature of the test 
Cost of additional diagnostic tests following an 
incorrect diagnosis £680 assumed to be the cost of a CT scan and a colonscopy. 
Cost of nurse administering Colonix test £8 Curtis 2007 cost of nurse consultation/procedure 
Cost of Barium Enema test £225 NHS ref costs 2005 
Cost of treating bleeding caused by 
colonoscopy £223 Curtis 2007 cost of bed day 
Cost of colonoscopy procedure £488 
National Tariff 2007-2008 F35 Large Intestine - 
Endoscopic or Intermediate Procedures, elective spell 
Cost of colonoscopy procedure (inpatient) £660 
National Tariff 2007-2008 F35 Large Intestine - 
Endoscopic or Intermediate Procedures, elective spell 
Cost of CT Virtual colonography test £488  
assumed to be same as cost of colonoscopy 
C Ferret suggests this cost is too high. 
Cost of CT scan £76 NHS ref cost RA08Z 
Cost of the Colonix test £125 A Llewellyn Colonix 
Cost of treating a fatal perforation £6,322 
Assumed to be the same as the cost of treating a perf 
F33 
Cost of inpatient visit £235 Curtis 2007 
Cost of hospital outpatient visit £85 Curtis 2007 outpatient followup attendance 
Cost of treating a bowel perforation caused by 
colonoscopy £6,322 
National Tariff 2007-2008, F33 Large Intestine - Major 
procedures w cc, non elective  
Cost of treating CRC diagnosed in Dukes A £7,251 Bowel Cancer Services: Costs and Benefits, April 2007 
Cost of treating CRC diagnosed in Dukes B £12,343 Bowel Cancer Services: Costs and Benefits, April 2007 
Cost of treating CRC diagnosed in Dukes C £18,830 Bowel Cancer Services: Costs and Benefits, April 2007 
Cost of treating CRC diagnosed in Dukes D £11,946 Bowel Cancer Services: Costs and Benefits, April 2007 
CT colonography sensitivity to cancer 0.938 Pickhardt 2003 
CT colonography sensitivity to IBD 0.938 assumed to be same as sensitivity to cancer 
CT colonography sensitivity to polyps 0.938 assumed to be same as sensitivity to cancer 
CT colonography test specificity 0.960 Pickhardt 2003 
Colonix sensitivity to cancer 0.896 Colonix trial data (combined) 
Colonix sensitivity to IBD 0.846 Colonix trial data (combined) 
Colonix sensitivity to polyps 0.896 Colonix trial data (combined) 
Colonix test specificity 0.682 Colonix trial data (combined) 
Colonix test threshold 2.000 suggested by Colonix 
DCBE test sensitivity to cancer 0.830 Smith 2001 
DCBE sensitivity to IBD 0.830 assumed to be same as sensitivity to cancer 
DCBE sensitivity to polyps 0.830 assumed to be same as sensitivity to cancer 
DCBE test specificity 0.993 Smith 2001 
Discount rate used for costs and QALYs 0.035   
probability of diagnosis in Dukes A 0.146 Stapley 2006 & stage transition probabilities. 
probability of diagnosis in Dukes A 0.420 Stapley 2006 & stage transition probabilities. 
probability of diagnosis in Dukes A 0.308 Stapley 2006 & stage transition probabilities. 
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probability of diagnosis in Dukes A 0.125 Stapley 2006 & stage transition probabilities. 
length of delay in diagnosis (years) due to a 
false negative 0.115 personal communication Ian Daniels 
CRC related mortality - Dukes A 0.037 
Cancer research UK website 5 year survival. CRC 
related mortality is assumed to be constant over the first 
5 years and 0 from years 6 onwards. 
CRC related mortality - Dukes B 0.085 Cancer research UK website 5 year survival. 
CRC related mortality - Dukes C 0.176 Cancer research UK website 5 year survival. 
CRC related mortality - Dukes D 0.504 Cancer research UK website 5 year survival. 
General yearly mortality 0.016 GAD life table ONS 2004-2006 
Prevalence of cancer 0.057 Colonix London trial data 
Prevalence of IBD 0.033 Colonix London trial data 
Prevalence NAD 0.900 Colonix London trial data 
Prevalence large polyps 0.010 Colonix London trial data 
Probability that a patient receiving and 
incomplete colonoscopy will have DCBE 0.600 personal communication Ian Daniels 
Yearly stage transition probability A to B 0.450 Tappenden 2007 ScHARR screening model 
Yearly stage transition probability B to C 0.541 Tappenden 2007 ScHARR screening model 
Yearly stage transition probability C to D 0.513 Tappenden 2007 ScHARR screening model 
Yearly stage transition probability high risk 
polyps to A 0.021 Tappenden 2007 ScHARR screening model 
Utility CRC diagnosed in Dukes A 0.740 Ness 1999 
Utility CRC diagnosed in Dukes B 0.700 Ness 1999 
Utility CRC diagnosed in Dukes C 0.500 Ness 1999 
Utility CRC diagnosed in Dukes D 0.240 Ness 1999 
Utility with IBD diagnosed 0.850  Allen 2005 
Utility with IBD undiagnosed 0.650  Allen 2005 
Utility with NAD 0.910  Ness 1999 
 
Table 2 – Distributions used in the PSA 
 
 
Variable Source 
Distribution 
type Parameters/Info 
DukesStage_dist Stapley 2006 Dirichlet 
Alphas list = List(43;124;91;37); Expected value: 0.146; 
0.420; 0.308; 0.125 
Cx_sens_cancer_dist Colonix (combined) trial data Beta 
alpha = Cx_testchars[Cx_threshold;3], beta = 
Cx_testchars[Cx_threshold;4]; Expected value: 0.896 
Cx_sens_polyps_dist Colonix (combined) trial data Beta 
alpha = Cx_testchars[Cx_threshold;3], beta = 
Cx_testchars[Cx_threshold;4]; Expected value: 0.896 
Cx_sens_IBD_dist Colonix (combined) trial data Beta 
alpha = Cx_testchars[Cx_threshold;1], beta = 
Cx_testchars[Cx_threshold;2]; Expected value: 0.846 
Cx_spec_dist Colonix (combined) trial data Beta 
alpha = Cx_testchars[Cx_threshold;5], beta = 
Cx_testchars[Cx_threshold;6]; Expected value: 0.682 
Col_complete_dist Bowles 2004 Beta alpha = 70, beta = 21; Expected value: 0.769 
Col_perf_dist Gatto 2003 Beta alpha = 77, beta = 39209; Expected value: 0.00196 
Col_fatal_perf_dist Gatto 2003 Beta alpha = 4, beta = 39282; Expected value: 0.000102 
Cx_contaminated_dist Colonix London trial data Beta alpha = 173, beta = 20; Expected value: 0.896 
Col_bleeding_dist Bowles 2004 Beta alpha = 13, beta = 9223; Expected value: 0.00141 
Prevalance_dist 
Prevalence - Cancer; polyps; IBD; 
NAD/other, Colonix London trial data Dirichlet 
Alphas list = List(12;2;7;188); Expected value: 0.0574; 
0.00957; 0.0335; 0.8995 
DCBE_sens_cancer_dist Smith 2001 Beta alpha = 39, beta = 8; Expected value: 0.830 
DCBE_spec_dist Smith 2001 Beta alpha = 1333, beta = 9; Expected value: 0.993 
CTCOL_sens_cancer_dist Pickhardt 2003 Beta alpha = 45, beta = 3; Expected value: 0.9375 
CTCOL_spec_dist Pickhardt 2003 Beta alpha = 1138, beta = 47; Expected value: 0.960 
Length_delay_dist Personal communication Ian Daniels Uniform Low Value = 4/52, High Value = 8/52; Expected value: 0.115 
COL_sens_cancer_dist Bressler 2004 Beta alpha = 979, beta = 39; Expected value: 0.962 
Utility_DukesA_dist Ness 1999, Tappenden 2007 Beta alpha = 269.4, beta = 94.6; Expected value: 0.740 
Utility_DukesB_dist Ness 1999 Beta alpha = 114.5, beta = 49.1; Expected value: 0.700 
Utility_DukesC_dist Ness 1999 Beta alpha = 132.9, beta = 132.9; Expected value: 0.5 
Utility_DukesD_dist Ness 1999 Beta alpha = 26, beta = 82.4; Expected value: 0.240 
Patient pathways when Colonix test is negative 
Further information is required to better understand the possible patient pathways when a 
negative Colonix test result is obtained. 
 
All symptomatic patients receiving a negative Colonix will be referred to an outpatient clinic. If 
the patients symptoms persist then it is likely that further diagnostic tests will be performed.  
The model uses the same length of delay for false negative Colonix test as for a false 
negative colonoscopy, barium enema or CT colonography result. Clinical opinion suggests 
that the likely length of delay in diagnosis caused by a symptomatic patient receiving a false 
negative test result is 4-8 weeks (personal communication Ian Daniels). Hence we assume 
that all patients will be correctly diagnosed 4-8 weeks after receiving a false negative 
diagnosis. In the sensitivity analysis a uniform distribution with a low value of 4 weeks and a 
high value of 8 weeks was used.  
 
It is important to model the costs and QALYs associated with being referred to an outpatient 
clinic.  As the model stands the most cost effective strategy is to simply refer all patients to 
the outpatient clinic and not to colonoscopy them until further diagnostics have been 
performed. Hence it is important to gain further information about the possible patient 
pathways when a negative Colonix test result is obtained. 
 
Colonix Trials 
Detailed information about the trial protocols should be included as part of the NICE 
submission. All questions in the QUADAS tool (see Appendix) should be answered and where 
the Colonix trial does not meet the QUADAS criteria the justification for this should be clearly 
explained. 
 
The following four trials look at the use of the Colonix tool as a device for diagnosing 
colorectal cancer. 
1) Guildford – symptomatic patients and cancer patients 
2) Honiton – asymptomatic volunteers 
3) Oxford – cancer patients 
4) London – symptomatic patients 
 
Information recorded for each study participant includes trial ID, age, sex, results of DNA 
analysis and cytological examination (if available), clinical diagnosis and pathology record (if 
available).  
 
Precise details on the study populations should be provided, for example Does the 
symptomatic population in the Colonix study consist of patients who have been referred by 
their GP? Also is there a definition of referral protocols that the GPs in the study use? – this 
would describe criteria which a patient will meet for entry into the study. 
 
In the Honiton trial patients do not receive the reference standard (colonoscopy) as it is 
extremely difficult to have colonoscopies done in healthy volunteers. As there may be some 
“silent” conditions in this asymptomatic group, thus the performance of the test can be slightly 
underestimated. 
 
Information on patient characteristics such as ages should be included.  Controls are all aged 
over 50. There are younger people in cancer and symptomatic groups.  In its screening 
version the test will target people over 50. All ages will be covered when symptomatic patients 
are tested.  
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Colonix test characteristics  
 
The population we are considering here is a symptomatic population. If such a population is 
used to determine test characteristics then as the number of patients with cancer will be small 
this will lead to considerable uncertainty surrounding the test sensitivity values. For this 
reason information from all four trials has been combined to calculate test characteristics. It is 
possible that combining the data from several trials in this way could introduce bias so this 
should be looked into by considering the trial designs and protocols. 
 
As it is thought that the Colonix test will have different characteristics for detecting different 
conditions separate sensitivity values are calculated for cancer, polyps, IBD. (A draw back of 
this approach is that the data sets will be smaller so there will be more uncertainty around test 
characteristic values).  
 
The Colonix data records the following conditions: 
dsnumtr finds 
Colonoscopy 
required 
0 NAD N 
1 Diverticulosis N 
2 
Hyperplastic polyps (small benign polyps not related to 
CRC) N 
3 Small adenomatous polyps (less than 10mm) N 
4 Large adenomatous polyps (10 mm and over) Y 
5 CRC Y 
6 Inflammatory conditions (except ulcerative colitis) Y 
7 Inflammatory conditions (ulcerative colitis) Y 
8 Malignancies (non-CRC) N 
9 Familial Adenomatosis Coli (FAP) Y? 
  Combinations of several conditions:   
12 Diverticulosis and hyperplastic polyps N 
13 Diverticulosis and small adenoma N 
16 Diverticulosis and inflammation  Diverticulitis  Y 
126 Diverticulosis, hyperplastic polyp(s), inflammation Y 
136 Diverticulosis, small adenomatous polyp(s), inflammation Y 
 
As the number of patients with large polyps (dsnumtr=4) is only 3 in the data currently 
available we have chosen to combine large polyps and cancer for the purpose of calculating 
test sensitivity. With a larger data set separate sensitivities for cancer and large polyps could 
be calculated. The test characteristics of Colonix have been calculated from study results for 
a range of DNA test thresholds. A DNA threshold of 2 has been selected for the base case. 
The uncertainty surrounding the tests characteristics is modelled using a beta distribution with 
parameters a=TP, b= FN for sensitivity and a=TN, b=FP for specificity. We have used a beta 
distribution in the model as this constrains the test characteristics to be between 0 and 1. 
Examples of sensitivity and specificity values are given in table 3. 
 
If a Colonix test has a ‘heavy’ level of faecal contamination then the test will need to be 
repeated. For this reason test results which had ‘heavy’ contamination were excluded from 
the test characteristics calculations. More details are provided in the costs section. The 
contamination threshold used was 1.5; i.e. samples were split into those acceptable and not 
acceptable for analysis using cab340=1.5 as the demarcation point. It is likely that the 
contamination rate may vary between a symptomatic and an asymptomatic population. The 
contamination rate from the London trial was 10.36% and this rate has been used in the 
modelling.  
 
 
 12 
Table 3 – Colonix test characteristics 
 
  
Sensitivity 
(IBD)   Sensitivity(cancer/polyps) Specificity   
Test 
threshold   a b   a b   a b 
1 0.923 12 1 0.985 66 1 0.310 125 278 
1.5 0.923 12 1 0.910 61 6 0.571 230 173 
2 0.846 11 2 0.896 60 7 0.682 275 128 
2.5 0.769 10 3 0.836 56 11 0.757 305 98 
3 0.692 9 4 0.776 52 15 0.804 324 79 
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Other diagnostic test characteristics 
 
A systematic review of test characteristics of diagnostic tests involved in the pathway of 
diagnosing colorectal cancer should be undertaken as part of the NICE submission. If results 
prove to be very sensitive to diagnostic test characteristics a more analytical 
approach/Bayesian evidence synthesis may be appropriate. 
 
Test characteristic values relating to diagnosis of IBD have not yet been researched. The 
model currently uses the same test characteristic values for sensitivity to IBD as for cancer. 
 
Estimates for the sensitivity and specificity of colonoscopy, barium enema and CT 
colonography have been taken from the following published studies: 
 
Colonoscopy 
Colonoscopy is viewed as the ‘gold standard’ for diagnostic testing as it allows a complete 
visualisation of the bowel. However, it is an imperfect ‘gold standard’ as complete 
visualisation is not always achievable and complication rates associated with colonoscopy are 
higher than those of other diagnostic methods. 
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Colonoscopies are considered to be complete when the caecum can be visualised and 
identified. An audit of several colonoscopy units in the UK showed that the average 
completion rate was 76.9% (Bowles et al, 2004). Caecal intubation was reported in 76.9% of 
procedures. However, when identification of the ileocaecal valve or intubation of the terminal 
ileum were the only criteria used for successful colonoscopy, just 56.9% of procedures could 
be considered complete. The caecal intubation rate varied considerable depending on the 
experience of the colonoscopist – from 69.2% to 83.6%. The first round of the UK screening 
pilot reported 416 incomplete colonoscopies and 3700 complete, so a completion rate of 90% 
(Steele 2004). It was suggested (person communication Ian Daniels) that the screening data 
does not include patients with poor bowel preparation so it is better to use the results of the 
audit, i.e. 76.9%. In the sensitivity analysis a beta distribution was chosen with 95% CI’s 
approximately matching the range reported (69.2% to 83.6%). 
Withdrawal time of the scope or equivalently length of duration of the exam is related to test 
sensitivity. Colonoscopist with mean withdrawal times of less than 6 minutes, those with mean 
withdrawal times of 6 minutes or more had higher rates of detection of any neoplasia (Barclay 
2006). 
 
Smith O’Dwyer 2001, N=1081, report a sensitivity rate of 97.5%,=36/37 for the detection of 
colorectal cancer and polyps over 10mm sensitivity. De Zwart et al (2001) gives a range 79%-
100%, and Rex et al (1997) report a sensitivity rate of 95%. Bressler 2004, N=10,187, report 
a sensitivity of 96%. As the Bressler study was so large this value has been used as the 
mean and a beta distribution with CIs that include a miss rate of approximately 3% 
(suggested by Ian Daniels) has been used. 
 
The other main outcomes reported in the colonoscopy literature were perforation and 
complication rates. These were reported in several studies including Ball et al (2004), De 
Zwart et al (2001), Thomas-Gibson et al (2002) and Bowles et al (2004). 
 Perforation rates were taken from (Gatto 2003) which reports a perforation rate of 0.2% and 
a fatal perforation rate of 0.01%. Bleeding following colonoscopy was taken from Bowles 2004 
which reports 13/9223=0.14%. 
 
Double contrast barium enema 
Double Contrast Barium Enema (DCBE) is a common diagnostic method which allows the 
whole bowel to be visualised. It is generally not as sensitive as other methods, such as 
colonoscopy, but complication rates are typically lower. 
 
The majority of the DCBE literature focused on sensitivity rates either for the identification of 
polyps over 10mm or cancer. In the literature, sensitivity rates are reported to range from 79% 
for radiologists in Booth et al (2005) to 97% in Law et al (1999). Other studies reported 
sensitivity rates in between, including Connolly et al (2002) 90.2%, Culpan et al (2002) 
90.6%, Rex et al (1997) 83%, Smith et al (2001) 83% and Tawn et al (2005) 85.9%. 
Values reported in Smith O’Dwyer 2001, N=1389, sensitivity=83%=39/47, Specificity 
=99%=1-9/1342 have been used in the model. 
 
Booth et al (2005) also indicated that double reporting may increase sensitivity rates of DCBE 
as the double reported sensitivity rates were up to 89% and this is consistent with other 
studies where DCBE are double reported such as Leslie et al (2002) and Law et al (1999) 
which report sensitivity rates of 93% and 97% respectively. 
 
Computerized tomographic (CT) virtual colonoscopy 
Computerized Tomographic (CT) virtual colonoscopy is a fairly new minimally invasive 
diagnostic procedure that generates a series of 2 and 3 dimensional images that allow for a 
full visualisation of the bowel. Recently accepted by the American Gastro Society. This 
procedure unlike conventional colonoscopy requires no intravenous sedatives to be 
administered and recovery times are much shorter. 
 
Gluecher et al (2002), N=50, reported a sensitivity rate of 82% for lesions larger than 10mm 
and a specificity of 90%. Johnson et al (2003), N=93, report a sensitivity of 75% (lower CI 
68%) and specificity of 73% (lower CI 66%). Pickhardt et al (2003), N=1233 asymptomatic, 
report a sensitivity of 93.8%(45/48) for lesions over 10mm with a specificity of 
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96%(1138/1185). White 2008, N=150, reports that for cancers VC had a sensitivity and 
specificity of 100% and 99.2% respectively and for detecting polyps >10mm, VC had a 
sensitivity and specificity (per patient) of 91% and 99.2% respectfully. 
 
The model uses the values from Pickhardt 2003 which is a large trial. 
 
Disease Prevalence age, etc 
 
The Colonix London trial (193 symptomatic patients at present but will be 500 when trial 
completes) is used to provide data on cancer, polyp and IBD prevalence in the symptomatic 
population. The mean patient age in the London trial was 65 with the majority of the patients 
aged between 50 and 80. We will obtain results for patient age equal to 55,65 and 75. 
The disease prevalence in the London trial is similar to that reported in Selvachandran 2002. 
 
The risk of cancer in a symptomatic patient is highly dependent on the symptoms experienced 
and on the setting (Thompson 2003). A range of values for prevalence should be considered 
in the sensitivity analysis.  
 
Duke’s stage distribution 
For cancer the model uses the Duke’s stage distribution on diagnosis to calculate survival and 
treatment costs for patients with CRC.  The model includes any HRQOL decrements due to a 
delay in diagnosis for patients receiving a false negative Colonix/colonoscopy test result. For 
a group of patients with CRC who experience a delay in diagnosis the stage distribution will 
change; as some patients may progress. This is modelled using annual stage transition 
probabilities (Tappenden 2004) and the estimated length of delay in diagnosis. 
 
Costs 
The main costs included in the model are those related to diagnosis. Diagnosis costs include 
diagnostic tests/procedures, costs of complications such as bleeding/perforation caused by 
colonoscopy, and further diagnostics due to unsatisfactory tests such as contaminated 
Colonix or incomplete colonoscopies. As a delayed diagnosis may effect Duke’s stage 
distribution colorectal cancer treatment costs are also included. 
 
The cost of a colonoscopy is taken from the NHS national tariff 2007-2008. We have used 
F35 - Large Intestine - Endoscopic or Intermediate Procedures, £488 elective spell tariff (<= 1 
day), and £172 for each additional day. Approximately 10% of patients will receive 
colonoscopy as an inpatient for medical or social reasons (e.g. heart problems, unfit, home 
alone) (personal communication Ian Daniels) so for these patients we have assumed the cost 
of colonoscopy is £488+£172=£660.  
 
It is assumed that patients receiving an incomplete colonoscopy will then have a BE or CT 
colonography and that this will require a subsequent outpatient attendance. It is estimated 
that 60% of patients will have BE and 40% CT colonography (personal communication Ian 
Daniels). The cost of barium enema is (£225 NHS ref costs 2005). As we do not have a 
specific cost for CT colonography the model currently assumes that the cost is the same as 
for colonoscopy. The cost of treating a bowel perforation is assumed to be £6322 (Large 
Intestine - Major Procedures w cc, non-elective, NHS ref costs 2007-2008) and the cost of 
treating bleeding is assumed to be one hospital bed day £223 (Curtis 2007).  
 
The cost of the Colonix test is £125 as suggested by Colonix. The test itself takes less than 5 
minutes where actual material collection takes 10 seconds. It is thought that the test would 
usually be administered by a qualified nurse and due to dietary recommendations an 
 15 
additional visit is likely to be involved (personal communication Ian Daniels). It thought that a 
GP will recommend a Colonix test and the patient will subsequently return and the test will be 
administered by a qualified nurse; the cost of a nurse consultation is £8 Curtis 2007. The 
model currently assumes that tests with heavy contamination will be repeated and the 
associated cost of this repeat test is included in the model. It is assumed that repeat tests will 
be satisfactory.  
Cost of Colonix = (cost of test +cost of nurse admin)*(1+proportion of tests contaminated). 
(£125+£8)*(1+0.104)=£146.78 
 
A dietary restriction could decrease the levels of contamination. Although dietary 
recommendations will be employed there is currently no data giving information on how 
dietary restrictions may affect the contamination rate so this had not been included in the 
modelling. 
 
It is assumed that patients who receive a false negative diagnosis will incur additional 
diagnosis costs. In the model this is currently set as the cost of a CT scan (£76 NHS ref costs 
2007) and a colonoscopy. The model includes CRC treatment costs which are dependent on 
Duke’s stage on diagnosis (YHEC report 2007). The model includes any changes to 
treatment costs due to a delay in diagnosis for patients receiving a false negative Colonix test 
result. For patients receiving a delay in diagnosis the stage distribution will change (as some 
patients may progress), hence mean treatment costs for this group are adjusted accordingly 
in the model. 
 
Survival and Health related quality of life 
For a NICE submission a systematic review of literature relating to utility values for CRC, IBD, 
and symptomatic patients would need to be undertaken. 
 
For patients who do not have colorectal cancer yearly survival rates are taken from the ONS 
lifetables, and are dependent on age and sex. For patients without colorectal cancer a utility 
multiplier of 0.91 is used (Tappenden 2007 -references Ness 1999). 
 
A proportion of patients will survive colorectal cancer and we have assumed that patients who 
survive to 5 years will not subsequently have metastatic recurrence. Survival in years 1-5 is 
assumed to be constant and dependent on stage. Stage dependent 5-year survival is taken 
from the cancer research uk website (see table below). It is assumed that survival in years 6 
onwards is the same as for an average person of the same age. 
 
 
Dukes' 
Stage 
modified 
Approximate 
frequency at 
diagnosis 
Approximate 
five-year 
survival 
A 11% 83% 
B 35% 64% 
C 26% 38% 
D 29% 3% 
 
 
Patients with high risk polyps will undergo a polypectomy and then undergo surveillance 
colonoscopy every 3 years until they have two consecutive negative results. It has been 
assumed that the life expectancy and utility for a patient who has had polyps removed is the 
same as for an average person of the same age. 
 
For patients with colorectal cancer utility values are taken from Ness 1999 and vary with 
Dukes stage (see Tappenden 2007 for details). Cancer patients are assumed to have the 
same utility for the rest of there life. This assumption is a simplification. A patient with terminal 
cancer may experience a decrease in quality of life as their cancer progressed. For a patient 
who survives cancer quality of life may improve but this would depend on any long term 
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effects of cancer treatment received, for example having part of their colon removed. It is 
assumed that a patient with a false negative test result who is experiencing a delay in 
diagnosis has the same utility as a patient who is diagnosed with colorectal cancer.  
 
For patient with IBD HRQOL is assumed to improve when a correct diagnosis is obtained. 
 
 
RESULTS AND DISCUSSION 
General Information on cost-effectiveness plane 
It is most usual for a new health intervention to be associated with increased QALYs and 
increased costs compared to the baseline treatment. Such an intervention would be in the top 
right quadrant of the cost-effectiveness plane, see figure below, and is considered cost 
effective if the incremental cost effectiveness ratio (ICER) is less than the willingness to pay 
threshold (£20K-£30K in the UK).  
 
An intervention associated with increased QALYS (effectiveness) and decreased costs (the 
bottom right quadrant) will always be considered cost effective. Similarly an intervention 
associated with decreased QALYS (effectiveness) and increased costs (the top left quadrant) 
will never be considered cost effective. 
 
The final possibility (the bottom left quadrant) is an intervention which decreases both costs 
and QALYs. Calculating the ICER can be misleading in this case. As both incremental costs 
and QALYs are negative the ICER will be positive. An intervention in this bottom left quadrant 
is considered cost effective if the ICER is greater that the willingness to pay threshold. This is 
because a high ICER relates to a large cost saving and a small QALY decrement.  
 
The incremental net monetary benefit (NMB) is a more illustrative result for interventions in 
this quadrant.  
 
inc. NMB = willingness to pay threshold * incremental QALYs  - incremental costs. 
 
For example if the incremental QALYS are -0.001 and the incremental costs are -£200 and 
the willingness to pay threshold is £20K then NMB=£20K*-0.001+£200=£180. 
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Clinical and cost outcomes 
 
The purpose of the following section is to present baseline results of the model. These results 
relate to a female population of age 65 and use a Colonix test threshold of 2. In this 
population the number of colonoscopies avoided by using Colonix in 1000 symptomatic 
patients is 626. 
 
 
 No Colonix   Colonix   
  mean 95% CI mean 95% CI 
Number of colonoscopys (as initial 
diagnostic or following positive Colonix) 1000   373.9 ( 327, 422) 
          
Mean cost of diagnosis £619 (£584, £659) £389 (£354,£423) 
 
Mean cost of cancer treatment (per patient 
with cancer) £13,653   £13,653   
          
Number of inappropriate* colonoscopies 900   288   
          
Number of patients obtaining a false 
negative Colonix or Colonoscopy test result 5.9   17.3   
          
Number of cancers detected (at initial 
colonoscopy) 42.2   37.8   
          
Cost per cancer detected £14,670   £10,288   
     
Population = 1000     
*inappropriate colonoscopies are assumed to be those performed in patients who do not have cancer, 
large polyps or IBD. 
 
Economic outcomes 
We performed a Monte Carlo simulation taking 10,000 samples and sampling from each of 
the distributions described in table 2. We present results of the probabilistic sensitivity 
analyses including the incremental cost effectiveness ratio (ICER) and incremental net 
monetary benefits (NMB). The model can calculate cost-effectivenes for a male or a female 
cohort using gender specific all-cause mortality data. The results presented here are for a 
female population but the results are very similar for a male population 
 
 
    Colonix     No Colonix   Incremental   
Age  Costs Eff. NMB Costs Eff. NMB Costs Eff. NMB 
55 Mean £1,171 13.57 £270,214 £1,401 13.57 £269,990 -£229 -0.000263 £224
  95% CI £782 13.26 £263,451 £1,022 13.26 £263,238 -£269 -0.001765 £234
    £1,683 13.81 £275,437 £1,898 13.81 £275,190 -£191 0.001087 £213
                  
65 Mean £1,166 10.24 £203,575 £1,396 10.24 £203,351 -£229 -0.000260 £224
  95% CI £783 10.02 £198,803 £1,019 10.02 £198,599 -£269 -0.001428 £241
    £1,648 10.41 £207,335 £1,867 10.41 £207,089 -£192 0.000788 £208
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75 Mean £1,168 6.75 £133,792 £1,397 6.75 £133,568 -£229 -0.000306 £223
  95% CI £779 6.63 £130,835 £1,019 6.63 £130,648 -£269 -0.001216 £244
    £1,665 6.84 £136,084 £1,874 6.84 £135,845 -£192 0.000432 £200
 
The following cost effectiveness acceptability curve (CEAC) and cost effectiveness scatter 
plot relate to the PSA results for a patient of age 65. The willingness to pay threshold that 
may be used by NICE is £20K and the CEAC demonstrates that at this threshold there is little 
uncertainty around the decision that Colonix is the most economically attractive option. The 
scatter plot presents the cost and effectiveness results for each of the 10,000 samples of the 
PSA. 
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Scenario Analysis 
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We show one way sensitivity analyses of cost of Colonix test and the length of delay in 
diagnosis and Colonix test threshold. The first graph shows that Colonix test is cost effective if 
the test price is less that £375. The second graph (which uses the standard price of £125) 
shows that Colonix is the most cost effective if the the delay associated with a false negative 
diagnosis is less than 1.8 years. 
Net Monetary Benefits
WTP = 20,000
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Net Monetary Benefits
WTP = 20,000
length of delay in diagnosis (years) due to a false negative
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The one-way sensitivity analysis on Colonix test threshold(below) highlights the need for 
further information on patient pathways if a negative Colonix result is obtained. A Colonix test 
with a high specificity but low sensitivity (a high threshold) is the most cost effective. We 
believe this is because further information is required to accurately represent the costs and 
patient pathways following a negative result in the model. We also believe that further 
information is required to correctly represent the uncertainty in the length of time until a 
correct diagnosis is reached when referred to an outpatient clinic in the model.  
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Incremental Net Monetary Benefits
WTP = 20,000
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The following 2-way sensitivity analysis of the variables length of delay in diagnosis and 
Colonix test threshold is a strategy graph. The shading on the graph indicates which strategy 
(Colonix or no Colonix) is the most cost effective for each combination of test threshold and 
length of delay. As the Colonix test threshold increases the test is less sensitive so there are 
more false negative diagnosis and hence more patient who receive a delay in diagnosis. For 
higher test thresholds the length of delay for which Colonix is the most cost effective is 
shorter. 
 
Net Monetary Benefit (wtp=20000.) Sensitivity Analysis on 
Colonix test threshold and length of delay in diagnosis (years) due to a false negative
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The following graph was calculated for a length of delay in diagnosis of 1 year as an example. 
It shows that the test threshold with highest net monetary benefit is 2 (although test threshold 
increments of 0.5 have been used). For Colonix test thresholds above 2.7 the most cost 
effective strategy is no Colonix in this case. 
 
Net Monetary Benefits
WTP = 20,000
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The following 1-way sensitivity analysis demonstrates that the results of the model are highly 
sensitive to the further diagnostic procedures used following a negative Colonix test. Currently 
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the model assumes that patients receiving a negative colonix result and whose underlying 
condition is NAD will not incur any further diagnostics costs. This assumption is unrealistic 
and informed opinions on the likely diagnostics such patients may receive when referred to an 
outpatient clinic are required to construct an accurate model. 
Net M onetary Benefits
WTP = 20,000
Cost of additional diagnostics for patients with NAD and negative Colonix
N
M
B
0.0 300.0 600.0 900.0
203.6K
203.6K
203.5K
203.5K
203.4K
203.4K
203.3K
203.3K
203.2K
203.2K
203.1K
203.1K
203.0K
203.0K
Colonix
No Colonix
Threshold Values:
Cost of additional diagnostics for patients with NAD and negative Colonix = 365.2
EV = 203.3K
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Discussion 
The results calculated here use a length of delay in diagnosis following a false negative test 
result of 4-8 weeks and a cost of additional diagnostics following a false negative of £76(=cost 
of CT scan). The results show that Colonix is more cost-effective than a strategy of no 
Colonix. The two strategies have very similar effectiveness but Colonix results in a cost 
saving of approximately £229 per patient.  
 
The main concerns with regard to the economics of Colonix 
The diagnostic pathways followed and diagnosis costs involved when a patient is referred to 
an outpatient clinic following a false negative need further research. 
 
The economic case for Colonix arises from the ability to avoid unnecessary colonoscopies 
therefore reducing cost and increasing efficient application of the current constrained 
colonoscopy services. If a patient who receives a negative Colonix result subsequently 
receives a colonoscopy then that advantage is lost. Therefore in order to demonstrate the 
benefit of Colonix it is necessary to demonstrate that a feasible and effective alternative 
diagnostic pathway exists for people who receive a negative result. This information is not 
collected in the current studies.  
 
The 2-way sensitivity analysis of the variables length of delay in diagnosis and Colonix test 
threshold explored this issue. Recall that as the Colonix test threshold increases the test is 
less sensitive so there are more false negative diagnosis and hence more patient who receive 
a delay in diagnosis. For higher test thresholds the length of delay for which Colonix is the 
most cost effective is shorter. 
 
To take this issue forward we suggest three potential courses of action: 
1) Collect further subjective clinical judgement relating to diagnostic pathways following 
a negative Colonix result. 
2) Examine what information of patient pathways is obtainable from existing Colonix 
trials – i.e. what subsequent diagnostic tests patients received following a negative 
result. 
3) Undertake a randomized control trial (RCT) to directly compare the two fully defined 
alternative diagnostic pathways (one pathway to represent the existing situation and 
one to include Colonix). 
 
 
Colonix Test threshold 
In a symptomatic population Colonix should be used as an exclusion test. 
It is important to ensure that cancer patients are identified by Colonix test. 
It is important to have a high negative predictive value, i.e. the test must be highly sensitive 
and not miss any cancer patients. 
 
In a screening population the emphasis would be on not having too many false positive 
results. It is important to avoid colonoscopies in healthy people. Hence the test needs to have 
a high specificity or equivalently a high positive predictive value. 
 
Hence the optimal test characteristics will be different for these different populations. It will be 
appropriate to use a different threshold for the colonix test in these different populations. 
Calculating the most cost-effective Colonix test threshold should help to inform this decision. 
 
Length of delay in diagnosis 
The one way sensitivity analysis for length of delay in diagnosis demonstrates that the results 
are quite sensitive to this variable. Hence it is advisable to obtain additional information 
relating to the possible length of delay as currently it is estimated from a single source 
(personal communication Ian Daniels). The 4-8 weeks length of delay suggested by Ian 
Daniels implies quite a low threshold for referral to colonoscopy from the outpatient clinic 
following a negative Colonix test result. Even with further clinical advice the length of delay 
will always be associated with a large degree of uncertainty. 
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IBD delay in diagnosis 
The model currently assumed that IBD treatment costs and survival are not effected by a 
delay in diagnosis. Validation of this assumption should be obtained. 
C Ferret will search on this issue 
 
Compliance Rate 
Due to its invasive nature colonoscopy has quite a low compliance rate – (80% Steele 2004 
screening trial). It is thought that Colonix will have much better patient acceptability than 
colonoscopy and also that colonoscopy compliance rates may be higher after a positive 
Colonix result. As there is no information on Colonix compliance we have chosen to exclude 
the issue of compliance from our modelling. 
 
Disutility associated with colonoscopy 
Colonoscopy is an invasive procedure which requires prior bowel preparation and sedation 
during the procedure. For some patients the procedure is likely to cause anxiety.  The 
disutility associated with colonoscopy is greater than that associated with the Colonix test but 
there is no evidence to prove this. For this reason this disutility has not been included in the 
modelling. A disutility corresponding to 1 day would be equal to 1/352 = 0.00274 
 
Morbidity associated with treating perforations 
The Surgical and Clinical Adhesions Research (SCAR) and SCAR-2 studies demonstrated 
that the burden of adhesions following lower abdominal surgery is considerable (Parker 
2005). Patients undergoing lower abdominal surgery(excluding appendicectomy) had a 5% 
risk of readmission directly related to adhesions in the 5 years following surgery. This risk has 
not been included in the modelling. 
 
Further work relating to NICE submission  
To produce a NICE submission in line with the guidance laid down in nice methods of 
appraisal the following would need to be undertaken: 
· A review of test characteristics of diagnostic tests involved in the pathway of 
diagnosing colorectal cancer. CT colonography, DCBE, CT scans possibly, etc 
· Systematic review of QOL data etc. 
· Obtain external validation of assumptions in the model structure 
· Detailed description of the Colonix clinical trials 
· Updating the model with new Colonix data if necessary. 
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Appendix 
 
NICE guidance on diagnostic technologies 
Diagnostic technologies can be used in different ways (for example, for disease identification, 
monitoring of disease progression and treatment, assessment of disease prognosis, or initial 
screening) and this should be reflected in the evidence submitted to the Institute. 
Evidence for the appraisal of diagnostic technologies should normally incorporate evidence 
on the accuracy of the diagnostic technology. It is also important to incorporate the predicted 
changes in health outcomes and costs as a result of treatment decisions based on the test 
result. 
The general principles guiding the assessment of the clinical and cost effectiveness of 
diagnostic technologies should be the same as for other technologies. However, particular 
consideration of the methods of analysis may be required, especially in relation to evidence 
synthesis. Evidence for the effectiveness of diagnostic technologies should include the costs 
and outcomes for people whose test results lead to an incorrect diagnosis as well as those 
who are correctly diagnosed. 
As for other technologies, RCTs have the potential to capture the pathway of care involving 
diagnostic technologies, but their feasibility and availability may be limited. Other study 
designs should be assessed on the basis of their fitness for purpose, taking into consideration 
the aim of the study (for example, to evaluate outcomes, or to evaluate sensitivity and 
specificity) and the purpose of the diagnostic technology. 
 
 
Prevalence – Thompson 2003 
The high prevalence of rectal bleeding,7 8 changes in bowel habit,9 and abdominal pain10 in 
the community relative to the incidence of bowel cancer means that most patients with these 
symptoms are at very low risk of cancer. Many of these symptoms are transient or cause no 
alarm, and over 80% of patients do not seek medical advice.7–11 Of those who do, only 40-
50% are referred to hospital.7 8 The risk of cancer in patients with rectal bleeding, for 
example, varies from 1:700 in the community8 to 1:30 in primary care,12 and 1:16 in a 
hospital surgical clinic.13 This means that 97% of patients seen in primary care with rectal 
bleeding do not have cancer. 
As abdominal pain and change in bowel habit are more common than rectal bleeding,14 they 
will have even lower predictive values for cancer. 
 
Formulae used in calculations 
Together with sensitivity and specificity for Colonix/colonoscopy the cancer risk is used to 
predict the number of false positive, true positive, false negative and true negative results 
using the following equations: 
 
test sens=True positives/disease  test spec=true negatives/disease free 
True positive=test sens * disease  True negative=test spec * (1-disease) 
False negative=(1-test sens) * disease  False positive=(1-test spec) * (1-disease) 
Here disease = the disease prevalence in the population (could be cancer/polyp/IBD 
prevalence). 
 
 
QUADAS tool 
Was the spectrum of patients representative of the patients who will receive the test in practice? 
Were selection criteria clearly described?   
Is colonoscopy likely to correctly classify the target condition? 
Is the time period between colonoscopy and Colonix test short enough to be reasonably sure  
that the target condition did not change between the two tests? 
Did the whole sample or a random selection of the sample receive verification using a colonoscopy  
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 or diagnosis?     
Did patients receive the same colonoscopy regardless of the Colonix test result? 
Was colonoscopy independent of the Colonix test (i.e. the Colonix test did not form part of  
colonoscopy)?     
Was the execution of the Colonix test described in sufficient detail to permit replication of the test? 
Was the execution of colonoscopy described in sufficient detail to permit its replication? 
Were the Colonix test results interpreted without knowledge of the results of colonoscopy? 
Were colonoscopy results interpreted without knowledge of the results of the Colonix test? 
Were the clinical data available when test results were interpreted as would be available when the  
test is used in practice?     
Were uninterpretable/intermediate test results reported? 
Were withdrawals from the study explained? 
 
